A method is presented for automated segmentation of vessels in two-dimensional color images of the retina. This method can be used in computer analyses of retinal images, e.g., in automated screening for diabetic retinopathy. The system is based on extraction of image ridges, which coincide approximately with vessel centerlines. The ridges are used to compose primitives in the form of line elements. With the line elements an image is partitioned into patches by assigning each image pixel to the closest line element. Every line element constitutes a local coordinate frame for its corresponding patch. For every pixel, feature vectors are computed that make use of properties of the patches and the line elements. The feature vectors are classified using a kappaNN-classifier and sequential forward feature selection. The algorithm was tested on a database consisting of 40 manually labeled images. The method achieves an area under the receiver operating characteristic curve of 0.952. The method is compared with two recently published rule-based methods of Hoover et al. and Jiang et al. The results show that our method is significantly better than the two rule-based methods (p < 0.01). The accuracy of our method is 0.944 versus 0.947 for a second observer.

No abstract

Artificial Intelligence (AI) has long promised to increase healthcare affordability, quality and accessibility but FDA, until recently, had never authorized an autonomous AI diagnostic system. This pivotal trial of an AI system to detect diabetic retinopathy (DR) in people with diabetes enrolled 900 subjects, with no history of DR at primary care clinics, by comparing to Wisconsin Fundus Photograph Reading Center (FPRC) widefield stereoscopic photography and macular Optical Coherence Tomography (OCT), by FPRC certified photographers, and FPRC grading of Early Treatment Diabetic Retinopathy Study Severity Scale (ETDRS) and Diabetic Macular Edema (DME). More than mild DR (mtmDR) was defined as ETDRS level 35 or higher, and/or DME, in at least one eye. AI system operators underwent a standardized training protocol before study start. Median age was 59 years (range, 22–84 years); among participants, 47.5% of participants were male; 16.1% were Hispanic, 83.3% not Hispanic; 28.6% African American and 63.4% were not; 198 (23.8%) had mtmDR. The AI system exceeded all pre-specified superiority endpoints at sensitivity of 87.2% (95% CI, 81.8–91.2%) (>85%), specificity of 90.7% (95% CI, 88.3–92.7%) (>82.5%), and imageability rate of 96.1% (95% CI, 94.6–97.3%), demonstrating AI’s ability to bring specialty-level diagnostics to primary care settings. Based on these results, FDA authorized the system for use by health care providers to detect more than mild DR and diabetic macular edema, making it, the first FDA authorized autonomous AI diagnostic system in any field of medicine, with the potential to help prevent vision loss in thousands of people with diabetes annually. ClinicalTrials.gov NCT02963441